% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Walter:298927,
      author       = {C. B. Walter and A. D. Hartkopf and A. Hein and P. A.
                      Fasching and H.-C. Kolberg and P. Hadji and H. Tesch and L.
                      Häberle and J. Ettl and D. Lüftner and M. Wallwiener and
                      V. Müller and M. W. Beckmann and L. L. Michel and E.
                      Belleville and H. Huebner and S. Uhrig and C. Goossens and
                      P. Wimberger$^*$ and C. Hielscher and J. Meyer and C.
                      Mundhenke and C. Kurbacher and R. Wuerstlein and M. Untch
                      and W. Janni and F.-A. Taran and M. P. Lux and D. Wallwiener
                      and S. Y. Brucker and A. Schneeweiss and T. N. Fehm and C.
                      Fremd$^*$},
      title        = {{C}haracteristics and prognosis of patients with primary
                      metastatic disease vs. recurrent {HER}2-negative, hormone
                      receptor-positive advanced breast cancer.},
      journal      = {The breast},
      volume       = {80},
      issn         = {0960-9776},
      address      = {Amsterdam [u.a.]},
      publisher    = {Elsevier},
      reportid     = {DKFZ-2025-00361},
      pages        = {104412},
      year         = {2025},
      abstract     = {Patients with first-line metastatic breast cancer (MBC)
                      comprise patients with de novo metastases (dnMBC) or
                      recurrent disease after primary breast cancer (rMBC). This
                      analysis aimed to explore the prognostic value of dnMBC
                      versus rMBC overall and particularly in subgroups according
                      to age and metastasis site, in addition to other prognostic
                      clinicopathological parameters in a first-line, hormone
                      receptor (HR)-positive, HER2-negative (HRpos/HER2neg)
                      population.Within the prospective PRAEGNANT MBC registry
                      (NCT02338167), 508 HRpos/HER2neg patients, receiving
                      first-line treatment for advanced disease, were identified.
                      Clinicopathological parameters (age, body mass index,
                      performance status, tumor grading, metastasis site and
                      therapy) were assessed according to metastatic status
                      (dnMBC, rMBC within 5 years of primary diagnosis (rMBC <5
                      years), rMBC after more than 5 years (rMBC ≥5 years)). Cox
                      regression analyses were performed to investigate whether
                      metastatic status influences progression-free survival (PFS)
                      and overall survival (OS).De novo metastatic disease was
                      present in 180 patients (35.4 $\%),$ whereas 132 patients
                      (26.0 $\%)$ had rMBC <5 years and 196 patients (38.6 $\%)$
                      had rMBC ≥5 years. Patients with dnMBC had the most
                      favorable prognosis. Relative to dnMBC, hazard ratios for
                      PFS were 1.75 $(95\%CI:$ 1.31-2.34) in rMBC<5 years and 1.25
                      $(95\%CI:$ 0.94-1.65) for rMBC ≥5 years. Subgroup-specific
                      differences were not observed.HRpos/HER2neg first-line MBC
                      patients have a more favorable prognosis if the disease was
                      previously not treated. This difference was similar across
                      all examined clinicopathological parameters. It may
                      therefore be beneficial to incorporate MBC categories as a
                      stratification factor in clinical trials.},
      keywords     = {Advanced breast cancer (Other) / First line therapy (Other)
                      / HER2-negative (Other) / Hormone receptor-positive (Other)
                      / Metastasis (Other) / de novo metastatic breast cancer
                      (Other)},
      cin          = {DD01 / HD01},
      ddc          = {610},
      cid          = {I:(DE-He78)DD01-20160331 / I:(DE-He78)HD01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:39952220},
      doi          = {10.1016/j.breast.2025.104412},
      url          = {https://inrepo02.dkfz.de/record/298927},
}